The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
NCT ID: NCT04664829
Last Updated: 2025-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
12 participants
INTERVENTIONAL
2020-10-01
2025-08-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour.
The investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
NCT00479674
Bexarotene in Treating Patients With Metastatic Breast Cancer
NCT00003752
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
NCT00472693
A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours
NCT01432145
A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer
NCT01094184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bexarotene and Capecitabine
Bexarotene
Administered orally once a day. Starting dosage: 200mg/m\^2
Capecitabine
Administered orally twice a day. Dosage: 1000mg/m\^2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bexarotene
Administered orally once a day. Starting dosage: 200mg/m\^2
Capecitabine
Administered orally twice a day. Dosage: 1000mg/m\^2
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients whose TNBC has progressed after prior taxane therapy in the (neo)adjuvant or metastatic setting, and have not received Capecitabine or 5-fluorouracil
* Females aged 21 years and older
* ECOG performance status 0 or 1
* Life expectancy greater than three months
* Patients have normal organ and marrow function
* Site(s) of disease amenable to serial bedside biopsies before, during and after study treatment
Exclusion Criteria
* Active symptomatic central nervous system (CNS) metastases
* Spinal cord compression not definitively treated with surgery and/or radiation
* Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures
21 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Medical Research Council (NMRC), Singapore
OTHER_GOV
National Cancer Centre, Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elaine Lim, MD
Role: PRINCIPAL_INVESTIGATOR
National Cancer Centre, Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Center Singapore
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BEXMET
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.